Litigation Details for Acorda Therapeutics, Inc. v. Alkermes plc (S.D.N.Y. 2023)
✉ Email this page to a colleague
Acorda Therapeutics, Inc. v. Alkermes plc (S.D.N.Y. 2023)
| Docket | ⤷ Sign Up | Date Filed | 2023-01-10 |
| Court | District Court, S.D. New York | Date Terminated | 2023-08-07 |
| Cause | 09:207 Application for order confirming award of arbitrators | Assigned To | Naomi Reice Buchwald |
| Jury Demand | None | Referred To | |
| Patents | 8,007,826; 8,354,437; 8,440,703; 8,663,685 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Acorda Therapeutics, Inc. v. Alkermes plc
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Acorda Therapeutics, Inc. v. Alkermes plc (S.D.N.Y. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-02-08 | 21 | Exhibit 2 | Alkermes—remain valid and unexpired: U.S. Patent Nos. 8,007,826 (“the ’826 patent”); …such patents and patent applications and any patent issuing thereon and extensions of any patents licensed…Alkermes’s patent rights (defined as “Elan Patent Rights”, which includes both issued patents and patent…licensed hereunder. Elan Patent Rights shall further include any patents or patent applications covering…(“the ’685 patent”); 8,354,437 (“the ’437 patent”); and 8,440,703 (“the ’703 patent”) (together | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
